Overview

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Status:
Recruiting
Trial end date:
2023-01-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Ipilimumab
Linrodostat
Nivolumab